A. Collis

发表

A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model

P. Tummino, I. Waddell, D. Ciccone, 2020, European Journal of Cancer.

Maximizing the outcome of early ADMET models: strategies to win the drug-hunting battles?

Jianling Wang, A. Collis, 2011, Expert opinion on drug metabolism & toxicology.

PYRROLIDINES BY 1,3-DIPOLAR CYCLOADDITION OF CONJUGATED AZOMETHINE YLIDES

D. E. Robinson, I. Coldham, A. Collis, 1995 .

An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.

Stephen D Pickett, Imtiaz Ahmed, Frank Halley, 2002, Journal of medicinal chemistry.

Ring expansion of aziridines to piperidines using the aza-wittig rearrangement

I. Coldham, A. Collis, R. Mould, 1995 .

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.

I. McLay, S. Phipps, M. Belvisi, 2001, Bioorganic & medicinal chemistry.

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.

I. McLay, N. Wilsher, M. Foster, 2001, Bioorganic & medicinal chemistry letters.

High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.

Dejan Bojanic, Wilfried Frieauff, D. Bojanic, 2010, Toxicological sciences : an official journal of the Society of Toxicology.

Section Review Central & Peripheral Nervous Systems: α1-Adrenoceptor antagonists as treatments for benign prostatic hyperplasia

M. Wyllie, A. Naylor, A. Collis, 1995 .

Central & Peripheral Nervous Systems a1 -Adrenoceptor antagonists as treatments for benign prostatic hyperplasia

A. Naylor, A. Collis, B. Kenny, 1995 .

Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.

Xiaozhang Zheng, Bingsong Han, Pui Yee Ng, 2018, Bioorganic & medicinal chemistry letters.

Evolution of the physicochemical properties of marketed drugs: can history foretell the future?

Peter Ertl, Bernard Faller, Giuliano Berellini, 2011, Drug discovery today.

Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279.

J. McElwee, Phani Ghanakota, Wenyan Miao, 2023, Journal of medicinal chemistry.

Synthesis of 4-phenylpiperidines by tandem Wittig olefination–aza-Wittig rearrangement of 2-benzoylaziridines

I. Coldham, A. Collis, R. Mould, 1995 .